Europe RNAi Therapeutics Market

Market Introduction

RNA interference (RNAi) is a vital biological process in which RNA molecules inhibit gene expression or translation, by neutralizing targeted mRNA molecules. RNAi is an essential research tool in cell culture and living organisms because synthetic dsRNA introduced into cells can induce the suppression of specific genes of interest. RNAi may be used for large-scale screens that orderly shutdown each gene in the cell, which can help to know the components necessary for a particular cellular event such as cell division. The pathway is also used as a practical tool in medicine, biotechnology, and insecticides.

Market Overview and Dynamics

The Europe RNAi therapeutics market is expected to reach US$ 324.33 million in 2027 from US$ 170.42 million in 2019. The market is anticipated to grow at a CAGR of 8.4% during 2019–2027. The growth of the market is attributed to some key driving factors such as growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions. However, high cost of RNAi therapy development is expected to obstruct the growth of the market to a certain extent during the forecast years.

Key Market Segments

In terms of molecule type, the small interfering RNAs (siRNA) segment accounted for the largest share of the Europe RNAi therapeutics market in 2019. In terms of route of administration, the pulmonary delivery segment accounted for the largest share of the Europe RNAi therapeutics market in 2019. In terms of application, oncology segment accounted for the largest share of the Europe RNAi therapeutics market in 2019. In terms of end user, research and academic laboratories segment accounted for the largest share of the Europe RNAi therapeutics market in 2019

Major Sources and Companies Listed

Several major primary and secondary sources associated with the Europe RNAi therapeutics market report are the World Health Organization (WHO), British Lung Foundation, Cancer Research UK, International Trade Administration (ITA), European Federation of Pharmaceutical Industries and Associations (EFPIA) and others.

Reasons to buy report

• It provides understanding of the Europe, RNAi therapeutics market landscape and identifies RNAi therapeutics market segments that are most likely to guarantee a strong return.
• It guides stay ahead of the race by comprehending the ever-changing competitive landscape for the Europe RNAi therapeutics market.
• It helps efficiently plan merger and acquisition, and partnership deals in the RNAi therapeutics market by identifying market segments with the most promising probable sales
• It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of RNAi therapeutics market performance of various segments pertaining to the Europe RNAi therapeutics market.
• It provides RNAi therapeutics market revenue forecast of the market based on various segments for the period from 2019 to 2027.

EUROPE RNAI THERAPEUTICS MARKET SEGMENTATION

By Molecule Type

• Small Interfering RNAs (siRNA)
• MicroRNA (miRNA)

By Route of Administration

• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Others

By Application

• Oncology
• Cardiovascular
• Respiratory Disorders
• Renal Diseases
• Genetic Disorders
• Neurodegenerative Disorders
• Infectious Diseases
• Others

By End User

• Research and Academic Laboratories
• Hospitals
• Diagnostic Laboratories

By Country

• Germany
• UK
• France
• Italy
• Spain

Company Profiles

• Sanofi
• GlaxoSmithKline plc
• Silence Therapeutics
• Alnylam Pharmaceuticals, Inc
• Arrowhead Pharmaceuticals, Inc

Europe RNAi Therapeutics Market Strategic Insights

Europe RNAi Therapeutics Market Segmentation Analysis

Europe RNAi Therapeutics Market Report Highlights

Europe RNAi Therapeutics Report Scope

Europe RNAi Therapeutics Market Country and Regional Insights